B. Huber joined the laboratory of Viral Oncology (LVO; chief R. Kirnbauer) at the MUV to evaluate an experimental broad-spectrum RG1-VLP HPV vaccine candidate. For her PhD thesis, she generated and analyzed the protective capacity of chimeric VLP targeting other HPV genera, including cutaneous HPV types that cause skin warts and are implicated in skin cancer development particularly in immunosuppressed individuals. As a postdoctoral researcher, she wants to further advance RG1-VLP vaccines by improving their thermostability, and to identify novel cross-neutralization epitopes particular to cutaneous HPV types.